Intravesical instillation-based mTOR-STAT3 dual targeting for bladder cancer treatment
Abstract Background Recent intravesical administration of adenoviral vectors, either as a single injection or in combination with immune checkpoint inhibitors, exemplified by cretostimogene grenadenorepvec and nadofaragene firadenovec, has demonstrated remarkable efficacy in clinical trials for non-...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2024-06-01
|
| Series: | Journal of Experimental & Clinical Cancer Research |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s13046-024-03088-7 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849332045798440960 |
|---|---|
| author | Dae Hoon Lee Jung Ki Yoo Ki Hwan Um Wootae Ha Soo Min Lee Junseong Park Min Jeong Kye Jungyo Suh Jin Woo Choi |
| author_facet | Dae Hoon Lee Jung Ki Yoo Ki Hwan Um Wootae Ha Soo Min Lee Junseong Park Min Jeong Kye Jungyo Suh Jin Woo Choi |
| author_sort | Dae Hoon Lee |
| collection | DOAJ |
| description | Abstract Background Recent intravesical administration of adenoviral vectors, either as a single injection or in combination with immune checkpoint inhibitors, exemplified by cretostimogene grenadenorepvec and nadofaragene firadenovec, has demonstrated remarkable efficacy in clinical trials for non-muscle invasive bladder cancer. Despite their ability to induce an enhanced immune reaction within the lesion, the intracellular survival signaling of cancer cells has not been thoroughly addressed. Methods An analysis of the prognostic data revealed a high probability of therapeutic efficacy with simultaneous inhibition of mTOR and STAT3. Considering the challenges of limited pharmaco-accessibility to the bladder due to its pathophysiological structure and the partially undruggable nature of target molecules, we designed a dual siRNA system targeting both mRNAs. Subsequently, this dual siRNA system was encoded into the adenovirus 5/3 (Ad 5/3) to enhance in vivo delivery efficiency. Results Gene-targeting efficacy was assessed using cells isolated from xenografted tumors using a single-cell analysis system. Our strategy demonstrated a balanced downregulation of mTOR and STAT3 at the single-cell resolution, both in vitro and in vivo. This approach reduced tumor growth in bladder cancer xenograft and orthotopic animal experiments. In addition, increased infiltration of CD8+ T cells was observed in a humanized mouse model. We provided helpful and safe tissue distribution data for intravesical therapy of siRNAs coding adenoviruses. Conclusions The bi-specific siRNA strategy, encapsulated in an adenovirus, could be a promising tool to augment cancer treatment efficacy and overcome conventional therapy limitations associated with “undruggability.” Hence, we propose that dual targeting of mTOR and STAT3 is an advantageous strategy for intravesical therapy using adenoviruses. Graphical Abstract The current investigation introduces an innovative conceptualization of bispecific short hairpin RNA (bs_shRNA) tailored for the equilibrated modulation of dual genes within a singular cellular context. This novel bs_shRNA was loaded into the genome of an oncolytic adenovirus to augment the therapeutic efficacy of oncolytic viral interventions via the targeted inhibition of mTOR and STAT3 pathways. In addition, the administration of BSV significantly reduced the volume of bladder cancer tumors, concomitantly facilitating an enhanced recruitment of CD8+T lymphocytes in vivo. |
| format | Article |
| id | doaj-art-82cfd578020d4122be752f044b76e28f |
| institution | Kabale University |
| issn | 1756-9966 |
| language | English |
| publishDate | 2024-06-01 |
| publisher | BMC |
| record_format | Article |
| series | Journal of Experimental & Clinical Cancer Research |
| spelling | doaj-art-82cfd578020d4122be752f044b76e28f2025-08-20T03:46:20ZengBMCJournal of Experimental & Clinical Cancer Research1756-99662024-06-0143112210.1186/s13046-024-03088-7Intravesical instillation-based mTOR-STAT3 dual targeting for bladder cancer treatmentDae Hoon Lee0Jung Ki Yoo1Ki Hwan Um2Wootae Ha3Soo Min Lee4Junseong Park5Min Jeong Kye6Jungyo Suh7Jin Woo Choi8Department of Pharmacology, College of Pharmacy, Kyung Hee UniversityDepartment of Pharmacology, College of Pharmacy, Kyung Hee UniversityDepartment of Pharmacology, College of Pharmacy, Kyung Hee UniversityR&D Center of Curigin Ltd., CuriginDepartment of Pharmacology, College of Pharmacy, Kyung Hee UniversityPrecision Medicine Research Center, College of Medicine, The Catholic University of KoreaR&D Center of Curigin Ltd., CuriginDepartment of Urology, Asan Medical Center, University of Ulsan College of MedicineDepartment of Pharmacology, College of Pharmacy, Kyung Hee UniversityAbstract Background Recent intravesical administration of adenoviral vectors, either as a single injection or in combination with immune checkpoint inhibitors, exemplified by cretostimogene grenadenorepvec and nadofaragene firadenovec, has demonstrated remarkable efficacy in clinical trials for non-muscle invasive bladder cancer. Despite their ability to induce an enhanced immune reaction within the lesion, the intracellular survival signaling of cancer cells has not been thoroughly addressed. Methods An analysis of the prognostic data revealed a high probability of therapeutic efficacy with simultaneous inhibition of mTOR and STAT3. Considering the challenges of limited pharmaco-accessibility to the bladder due to its pathophysiological structure and the partially undruggable nature of target molecules, we designed a dual siRNA system targeting both mRNAs. Subsequently, this dual siRNA system was encoded into the adenovirus 5/3 (Ad 5/3) to enhance in vivo delivery efficiency. Results Gene-targeting efficacy was assessed using cells isolated from xenografted tumors using a single-cell analysis system. Our strategy demonstrated a balanced downregulation of mTOR and STAT3 at the single-cell resolution, both in vitro and in vivo. This approach reduced tumor growth in bladder cancer xenograft and orthotopic animal experiments. In addition, increased infiltration of CD8+ T cells was observed in a humanized mouse model. We provided helpful and safe tissue distribution data for intravesical therapy of siRNAs coding adenoviruses. Conclusions The bi-specific siRNA strategy, encapsulated in an adenovirus, could be a promising tool to augment cancer treatment efficacy and overcome conventional therapy limitations associated with “undruggability.” Hence, we propose that dual targeting of mTOR and STAT3 is an advantageous strategy for intravesical therapy using adenoviruses. Graphical Abstract The current investigation introduces an innovative conceptualization of bispecific short hairpin RNA (bs_shRNA) tailored for the equilibrated modulation of dual genes within a singular cellular context. This novel bs_shRNA was loaded into the genome of an oncolytic adenovirus to augment the therapeutic efficacy of oncolytic viral interventions via the targeted inhibition of mTOR and STAT3 pathways. In addition, the administration of BSV significantly reduced the volume of bladder cancer tumors, concomitantly facilitating an enhanced recruitment of CD8+T lymphocytes in vivo.https://doi.org/10.1186/s13046-024-03088-7Bladder cancermTORSTAT3siRNACancer therapy |
| spellingShingle | Dae Hoon Lee Jung Ki Yoo Ki Hwan Um Wootae Ha Soo Min Lee Junseong Park Min Jeong Kye Jungyo Suh Jin Woo Choi Intravesical instillation-based mTOR-STAT3 dual targeting for bladder cancer treatment Journal of Experimental & Clinical Cancer Research Bladder cancer mTOR STAT3 siRNA Cancer therapy |
| title | Intravesical instillation-based mTOR-STAT3 dual targeting for bladder cancer treatment |
| title_full | Intravesical instillation-based mTOR-STAT3 dual targeting for bladder cancer treatment |
| title_fullStr | Intravesical instillation-based mTOR-STAT3 dual targeting for bladder cancer treatment |
| title_full_unstemmed | Intravesical instillation-based mTOR-STAT3 dual targeting for bladder cancer treatment |
| title_short | Intravesical instillation-based mTOR-STAT3 dual targeting for bladder cancer treatment |
| title_sort | intravesical instillation based mtor stat3 dual targeting for bladder cancer treatment |
| topic | Bladder cancer mTOR STAT3 siRNA Cancer therapy |
| url | https://doi.org/10.1186/s13046-024-03088-7 |
| work_keys_str_mv | AT daehoonlee intravesicalinstillationbasedmtorstat3dualtargetingforbladdercancertreatment AT jungkiyoo intravesicalinstillationbasedmtorstat3dualtargetingforbladdercancertreatment AT kihwanum intravesicalinstillationbasedmtorstat3dualtargetingforbladdercancertreatment AT wootaeha intravesicalinstillationbasedmtorstat3dualtargetingforbladdercancertreatment AT soominlee intravesicalinstillationbasedmtorstat3dualtargetingforbladdercancertreatment AT junseongpark intravesicalinstillationbasedmtorstat3dualtargetingforbladdercancertreatment AT minjeongkye intravesicalinstillationbasedmtorstat3dualtargetingforbladdercancertreatment AT jungyosuh intravesicalinstillationbasedmtorstat3dualtargetingforbladdercancertreatment AT jinwoochoi intravesicalinstillationbasedmtorstat3dualtargetingforbladdercancertreatment |